Sanovas Fortifies Arsenal of Precision Medicine Patents with Award of U.S. Patent for PhotoDynamic Therapy with Localized Delivery

SAN RAFAEL, Calif., Aug. 21, 2018 /PRNewswire/ -- ­Sanovas, Inc., (www.sanovas.com) San Rafael, CA. U.S.A. and Suzhou, China, an internationally-recognized, privately-financed biomedical device development company, announced today that the United States Patent and Trademark Office issued patent 10,029,115 for the company's PhotoDynamic Therapy with Localized Delivery. This Patent builds upon its predecessor patent of the same name and the company's patents related to Systems and Methods for the Treatment of Hypoxic Tumors with Localized Oxygenation. 

Sanovas' Minimally Invasive Nano Oncology System (MINOS™) enables clinicians to measure tumor pathophysiology and to reverse hypoxia in therapy resistant tumors, in real time. The MINOS system provides intra-tumoral diagnostics in combination with the direct injection of oxygenating agents into hypoxic cancer tissues to sensitize the tumor microenvironment to chemotherapy and radiation therapy. MINOS enables the precise positioning of localized therapies to very small diameter, less than 3 millimeter, anatomic sites in the periphery of the lung and throughout the body, while mitigating systemic toxicities and undesired side effects.

"Sanovas' MINOS technology provides doctors with a set of excellent precision tools to defeat invasive cancers. The advent of CT scanning for early lung cancer means many patients are being detected when the tumor is still small and curable. This new technology allows for minimally invasive approaches to diagnosis and treatment – all done with minimal side effects and maximum patient comfort," stated Stephen C. Schimpff, MD former CEO of the University of Maryland Medical Center, past Chair of the Board of Governors of The Clinical Center of the National Institutes of Health (NIH), renowned healthcare author and thought leader.

"This system is highly important and most useful for the early detection, imaging and therapeutic treatment of pulmonary and other neoplasms," stated Zhen Cheng PhD, Associate Professor of Radiology and the Molecular Imaging Program at the Canary Center for Cancer Early Detection, the Bio-X Program and the Stanford Cancer Center at Stanford University.

"This new method captures the essence of precision medicine in its formulaic approach to diagnosing, modulating and treating the tumor micro environment to achieve definitive tumor kills in real time. Subject to clinical trials, this approach to precision medicine represents the future of first line solutions to curing early stage (I, II, III) cancers and even solitary malignancies," remarked Rosa Cuenca MD, Surgical Oncologist, and Director of The Diagnostic Center, Titus Regional Medical Center, and Clinical Professor of Surgery, LSU Shreveport. "Having a war chest of nanotechnologies to access surgical sites with minimal invasion to ablate tumor and augment tumor immunotherapy is a game changer."

"Every fireman knows the recipe for a fire. Heat, fuel and oxygen. This simple equation has not been confirmable or reproducible when applying this formula for the destruction of airway accessible malignant tumors. There is a mountain of peer reviewed data to support the robust tumor ablation capabilities of PDT in the aero-digestive track when conditions are favorable. In the proper setting, PDT has been unequivocally proven to work. It does not cause tumor resistance. It is not immutagenetic. It does not cross react with other oncologic treatments. 

To date, the limitation has been the planning complexity to confirm the proper delivery of directed heat, fuel and oxygen. The Sanovas patent addresses all these components in what is an amazingly simple and elegant delivery system. It absolutely confirms directed therapy without probable bystander effects. It confirms appropriate oxygen presence as well as delivery of the PDT photosensitizing agent into the tumor. I await with anticipation clinical trials that confirm the significant potential of this system to address the devastating impact of lung cancer on our patients," stated Gordon Downie, MD, PhD, Director of Interventional Pulmonology at Titus Regional Medical Center and Clinical Professor of Medicine, LSU-Shreveport.

"MINOS is a comprehensive treatment technique that points to the future of precision medicine and to treating therapy resistant cancers," stated Larry Gerrans, the patent's author and the President and CEO of Sanovas. "This is a new therapeutic solution with a strong potential to improve cancer treatments, prolong survival and save millions of lives, globally."

Done with minimally invasive technologies, MINOS can be used when open surgery or external beam radiation would be detrimental or even contraindicated to the patient with other disease entities such as chronic pulmonary disease or heart failure.

About Sanovas  
Sanovas, Inc. is a life science company commercializing breakthrough medical technologies to save lives.

Media Contact:
Steve Goldsmith
415-729-9391 x1023
[email protected]

SOURCE Sanovas

Related Links

http://www.sanovas.com